

Post-infectious IBS

G. Boeckxstaens KU Leuven, University Hospital Leuven Leuven, Belgium



Food allergy, food sensitivity, food intolerance and ... IBS?

- IBS is a symptom-based diagnosis
- 4-10 % of Western population
- Changes in stool consistency or frequency, discomfort and/or pain
- No detectable abnormalities on endoscopy, radiological imaging or lab tests
- Limited insight in pathophysiology disappointing treatment
- Heterogenous patient population
- Common in all patients = abdominal pain





What are the triggers leading to mast cell activation in IBS?

DIZZINESS

Food Stress Infection FOOD POISONING SIGNS AND SYMPTOMS ABDOMINAL CRAMPS Understanding of the fail





.

TARG

Barbara et al., Gastroenterology 2019



Campylobacter-induced gastrointestinal complaints 3 months following infection

99 subjects infected with Campylobacter jejuni: 22 had persistent GI symptoms after 3 months – 45% fulfilled Rome III criteria for IBS



Jalanka et al., Gut 2023



Symptoms of post-infectious IBS can persist for years

- Walkerton, Ontario, Canada:
- in 2000, heavy rainfall washed livestock fecal resdiue into drinking water supply
- Contamination with E. coli, Campylobacter jejuni and other pathogens affecting at least 2300 locals (6 died)
- Large cohort was followed during 8 years









Risks factors of PI-IBS and mechanisms underlying abnormal pain signaling





Abdominal pain is transmitted via extrinsic afferent nerve fibers innervating the intestine



Adapted from: Brierley & Linden, Nat Rev Gastro Hepatol 2014

Increased pain perception



What do we know about the pathophysiology of IBS? Abnormal pain signaling





Wouters et al., Gastroenterol 2016; Balemans et al., Am J Physiol 2019



Role of histamine in increased excitability of submucosal neurons and visceral afferents in PI-IBS

Contamination of drinking water in 2 Belgian villages (Hemiksem and Schelle) – rectal biopsies collected after 2 years from controls, infected non-IBS and PI-IBS



Balemans et al., Sci Reports 2017



Immune cells and mediators potentially interacting with afferent nerves





Brierley & Linden, Nat Rev Gastroenterol Hepatol 2014

- Neural activation blocked by antagonist of serotonin, histamine, proteases
- Increased numbers of mast cells in intestinal biopsies
- Increased release of histamine and proteases in supernatant of IBS biopsies



What are the triggers for mast cell activation?



Loss of tolerance to food antigens in IBS?





Aberrant immune response triggered against food antigens during gastrointestinal infection?





Aberrant immune response triggered against food antigens during gastrointestinal infection?





Is loss of oral tolerance to OVA triggering abnormal pain signaling in response to OVA re-exposure?





Long-lasting visceral hypersensitivity evoked by re-exposure to OVA following infection with *C. rodentium*



No VHS in mast cell deficient mice



Blockade of OVA-specific IgE with monoclonal IgE antibody prevents visceral hypersensitivity





Food-induced IgE-mediated mast cell activation as underlying mechanism of visceral hypersensitivity (abdominal pain)



Aguilera-Lizarraga et al., Nature 2021



Mucosal reaction to food antigen injection in IBS patients

- IBS patients (neg skin prick test and neg serum IgE levels) vs healthy controls
- Food antigens (wheat, gluten, milk, soy) injected into the mucosa to trigger MC activation
- Development of oedema and visibility of vasculature was scored after 12 minutes

Antigen injection



Mucosal reaction to food antigen injection in IBS patients

- IBS patients (neg skin prick test and neg serum IgE levels) vs healthy controls
- Food antigens (wheat, gluten, milk, soy) injected into the mucosa to trigger MC activation
- Development of oedema and visibility of vasculature was scored after 12 minutes









IgE-mediated mast cell activation in IBS patients

IgE TCCF



Aguilera-Lizarraga et al., Nature 2021



scRNAseq of rectal biopsies collected from healthy volunteers and IBS patients





H. Hussein (unpublished)



Mast cells as potential target for treatment of IBS



Aguilera-Lizarraga et al., Nature 2021



Wouters et al., Gut 2015



Effect of the H₁R antagonist ebastine on weekly global relief and abdominal pain in IBS

- Placebo-controlled randomized phase 2b trial
- 12 weeks H1R antagonist ebastine vs placebo
- 203 non-constipated IBS patients Rome III





Adapted from Rothenberg, NEJM 2021



Food allergy, food sensitivity, food intolerance and ... IBS?



Caminero et al., Nat Rev Gastro Hepatol 2019



Acknowledgements

